Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

526
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
526
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

573
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
573
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

678
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
678
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

612
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
612
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

486
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
486

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thermal Ablation with or without Liver Transplantation for Hepatocellular Carcinoma in Older Adults with Child-Pugh Class A Cirrhosis.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Impact of High Baseline Post-Void Residual Volume on Outcomes Following Prostatic Artery Embolization.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Prostatic Urethral Angle and Symptom Response after Prostatic Artery Embolization: A Retrospective Study.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Society of Interventional Radiology (SIR) 2026 Practice Guidance Document for Prostatic Artery Embolization.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Intravascular Ultrasound in Chronic Limb-Threatening Ischemia Endovascular Revascularization: A Multidisciplinary Survey of Clinical Practices and Operator Perceptions.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.

The Lancet. Oncology·2026
Same journal

Impact of Canadian Association of Radiologists and Fukuoka Recommendations on MRI Utilization for Surveillance of Incidental Pancreatic Cysts.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same journal

The Unseen Aneurysm: Can Artificial Intelligence Bridge the Diagnostic Gap in Angiogram-Negative Subarachnoid Hemorrhage?

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same journal

Acute Non-Traumatic Urinary Tract Emergencies: The Central Role of CT Imaging and the Emerging Role of Photon-Counting CT.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same journal

Reporting Completeness of Diagnostic Accuracy Studies: A Meta-Review of Investigations on Adherence to STARD 2015.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same journal

The Heat is On for Canadian Health Care.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same journal

Growth, Gaps, and Emerging Priorities in Environmentally Sustainable Medical Imaging.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K

Prostate Artery Embolization for Benign Prostatic Hyperplasia: Current Status.

Anirudh Mirakhur1, Justin P McWilliams1

  • 1Division of Interventional Radiology, Department of Radiological Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, USA.

Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes
|November 27, 2016
PubMed
Summary
This summary is machine-generated.

Prostate artery embolization offers a safe and effective minimally invasive treatment for benign prostatic hyperplasia symptoms. Further research is needed to fully establish this technique for widespread benign prostatic hyperplasia management.

Keywords:
EmbolizationInterventional radiologyLower urinary tract symptomsProstatic hyperplasiaTransurethral resection of prostate

More Related Videos

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.5K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.8K

Related Experiment Videos

Last Updated: Mar 11, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.5K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.8K

Area of Science:

  • Urology
  • Interventional Radiology

Background:

  • Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms.
  • Medication and surgical options have limitations.
  • Minimally invasive treatments are increasingly sought.

Purpose of the Study:

  • To review prostate artery embolization (PAE) for benign prostatic hyperplasia.
  • To discuss benefits and technical challenges of PAE.
  • To evaluate current evidence for PAE in BPH management.

Main Methods:

  • Review of current literature on prostate artery embolization.
  • Analysis of safety and efficacy data.
  • Discussion of patient selection and technical aspects.

Main Results:

  • PAE is a safe and effective option for BPH.
  • It is suitable for patients refractory to medication or unsuitable for surgery.
  • Technical challenges exist but are manageable.

Conclusions:

  • PAE is a viable treatment for symptomatic BPH.
  • It offers an alternative for specific patient groups.
  • Long-term, randomized studies are required for definitive establishment.